Skip to main content

Stomach Cancer/Gastric Cancer Treatment Market to Reach USD 8.20 Billion by 2026; Rapid Adoption of PD-1 Inhibitors for Treating Gastric Cancers to Boost the Market: Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Feb. 11, 2020 (GLOBE NEWSWIRE) — The global Stomach Cancer Treatment Market size is expected to reach USD 8.20 billion by 2026, exhibiting a CAGR of 15.3% during the forecast period. One of the major forces behind the rise of this market is the increasing prevalence of cancer in general and stomach cancer in particular worldwide. The GLOBOCAN 2018, which is a report on the global burden of cancer produced by the International Agency for Research on Cancer (IARC), estimates that in 2018, new cancer cases will be around 18 million and cancer-related deaths will be close to 9.6 million. Further, stomach cancer will account for 8.2% of the new cancer cases. Statistics released by the World Cancer Research Fund (WCRF) substantiate the IARC’s findings. According to the WCRF, gastric cancer is the fourth mostly commonly diagnosed cancer worldwide, with 1 million new reported cases. As the incidence of stomach cancer increases across the globe, the demand for stomach cancer drugs will rise commensurately, spelling good news for this market.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/stomach-gastric-cancer-treatment-market-102094

Fortune Business Insights™ shares the above information in its new report, titled “Stomach Cancer/Gastric Cancer Treatment Market Size, Share & Industry Analysis, By Drug Type (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists, and Others), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST), and Gastric Neuroendocrine Tumors (gNET)), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2019-2026”. According to the report, the market value stood at USD 2.61 billion in 2018. The other highlights of the report include:Elaborative overview of the industry outlook;360-degree analysis of the factors driving and restraining the market;Careful study of the different market segments; andDetailed research into the regional and competitive dynamics influencing the market growth.Encouraging Pipeline Candidates to Create Investment OpportunitiesPotential pipeline candidates are being researched and developed as targeted therapies to treat gastric cancers. Targeted therapies involve specialized drugs that halt the spread of cancer by intervening or targeting specific molecules. For instance, Pfizer and EMD Serono Inc., is currently engaged in developing a drug called Avelumab for the treatment of advanced gastric cancer. Similarly, OncoQR ML recently declared that it has attained proof-of-concept (PoC) for its leading oncology product for gastrointestinal cancer called OQR100 (G17/little gastrin). Such research undertakings are emerging as one of the defining Stomach Cancer Treatment Market trends as these projects are encouraging players to focus their investment energies on enhancing their R&D capacities.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/stomach-gastric-cancer-treatment-market-102094

Growing Prevalence Stomach Cancer to Drive the Market in Asia-PacificAsia-Pacific generated USD 1.01 billion in revenue in 2018. The region is, therefore, expected to dominate the gastric cancer treatment market share in the upcoming decade. The main reason for this is the increasing incidence of gastric cancer cases, primarily in India and China. The World Health Organization (WHO) estimates that in 2018 there were 456,124 stomach cancer cases in China. Coupled with this is the rising frequency of new product launches, both of which are propelling the regional market.  In North America, increasing preference for targeted therapies, rising incidence of stomach cancer, and growing R&D efforts by pharmaceuticals is spiking the demand for gastric carcinoma drugs in the region. Supportive government measures and favorable health reimbursement policies will bode well for the gastric carcinoma treatment market in Europe.Active and Timely Regulatory Approvals to Novel Drugs to Fuel CompetitionAccording to the Stomach Cancer Treatment Market analysis, regulatory clearances to innovative products will push the limits of competition in this market. Besides these approvals, many players are collaborating with each other to deepen their footprint in the gastric carcinoma drugs market.Industry Developments:January 2020: Blueprint Medicines Corp’s oral drug, Ayvakit, received US FDA’s green light. The drug is designed to treat gastrointestinal stromal tumor, a rare cancer that affects the stomach and small intestine.April 2019: The German pharmaceutical giant, Boehringer Ingelheim, and PureTech Health partnered so that Boehringer could use PureTech’s lymphatic targeting system to directly deliver the company’s gastric cancer candidate into the gut lymphatics.
List of Top Players Covered in the Stomach Cancer/Gastric Cancer Treatment Market Report:Jiangsu Hengrui Medicine Co., Ltd.TAIHO PHARMACEUTICAL CO., LTD.Celltrion Inc.Novartis AGF. Hoffmann-La Roche LtdIpsen PharmaBristol-Myers Squibb CompanyBayer AGMerck & Co., Inc.Eli Lilly and Company
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/stomach-gastric-cancer-treatment-market-102094

Detailed Table of Content:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of Stomach Cancer – For Key CountriesRegulatory Scenario – For Key Countries/RegionsReimbursement Scenario – For Key Countries/RegionsNew Product LaunchesKey Industry Developments – Mergers, Acquisitions and PartnershipsGlobal Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis, Insights and Forecast – By Drug TypeProgrammed Cell Death Protein 1 (PD-1) InhibitorsHuman Epidermal Growth Factor Receptor (HER2) AntagonistsVascular Endothelial Growth Factor Receptor (VEGFR) AntagonistsOthersMarket Analysis, Insights and Forecast – By Disease IndicationGastric AdenocarcinomaGastrointestinal Stromal Tumor (GIST)Gastric Neuroendocrine Tumor (gNET)Market Analysis, Insights and Forecast – By Route of AdministrationOralParenteralMarket Analysis, Insights and Forecast – By Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & AfricaTOC Continued….!

Request for Customization:  https://www.fortunebusinessinsights.com/enquiry/customization/stomach-gastric-cancer-treatment-market-102094

Have a Look at Related Reports:Human Papillomavirus (HPV) Vaccines Market Size, Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026U.S. Biosimilars Market Size, Share and Industry Analysis By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies, Others), By Disease Indication (Cancer, Autoimmune Diseases, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast, 2019 – 2026Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Size, Share and Industry Analysis by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma), and Regional Forecast 2019-2026Lung Cancer Therapeutics Market Size, Share and Industry Analysis By Therapy (Targeted, Therapy, Immunotherapy, Chemotherapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast 2019-2026Breast Cancer Therapeutics Market Size, Share and Industry Analysis By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Cancer Type (Hormone Receptor, HER2+), and Regional Forecast, 2019 – 2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release https://www.fortunebusinessinsights.com/press-release/stomach-gastric-cancer-treatment-market-9572

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.